Drug intelligence / Profile preview

[18F]VM4-037

Development stage
Phase 2
Lead developer
MAASTRO Clinic
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

[18F]VM4-037 is a fluorine-18 labeled radiopharmaceutical developed as a positron emission tomography (PET) imaging tracer. It is a small molecule sulfonamide-based compound that specifically targets Carbonic Anhydrase IX (CAIX), a cell-surface protein that is significantly upregulated under hypoxic conditions in various solid tumors, most notably in renal cell carcinoma. By binding to CAIX, [18F]VM4-037 serves as a non-invasive surrogate marker for tissue hypoxia, which is often associated with tumor aggressiveness, poor prognosis, and resistance to conventional therapies. While clinical trials have evaluated its efficacy in imaging stage 4 solid tumors, its utility can be limited by high physiological uptake in the liver and kidneys, which may obscure tumor-specific signals in those regions.

Other names
[18F]-VM4-037Fluorine-18 VM4-037Fluorine18 VM4-037Fluorine 18 VM4-037
02

Targets

CA1 (Carbonic anhydrase 1)CA2 (Carbonic Anhydrase 2)CA9 (Carbonic anhydrase IX)CA12 (Carbonic anhydrase XII)

Beyond the preview

Go deeper on [18F]VM4-037.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]VM4-037.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call